 Connection
Patrick Johnston to Lymphoma, Non-Hodgkin
This is a "connection" page, showing publications Patrick Johnston has written about Lymphoma, Non-Hodgkin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
6.876 |
|
|
|
-
Wudhikarn K, Johnson BM, Inwards DJ, Porrata LF, Micallef IN, Ansell SM, Hogan WJ, Paludo J, Villasboas JC, Johnston PB. Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis. Transplant Cell Ther. 2023 03; 29(3):176.e1-176.e8.
Score: 0.707
-
Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022 09; 28(9):610-617.
Score: 0.683
-
Khurana A, Novo M, Nowakowski GS, Ristow KM, Spinner RJ, Hunt CH, King RL, Lachance DH, Habermann TM, Micallef IN, Johnston PB. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021 03 09; 5(5):1379-1387.
Score: 0.625
-
Khurana A, Micallef IN, LaPlant BR, Patrick O'Neill B, Habermann TM, Ansell SM, Inwards DJ, Porrata LF, Paludo J, Bisneto JCV, Johnston PB. Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. Biol Blood Marrow Transplant. 2020 12; 26(12):2217-2222.
Score: 0.602
-
Johnston PB, Wiseman GA, Micallef IN. Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma. Bone Marrow Transplant. 2008 Jun; 41(11):919-25.
Score: 0.255
-
Johnston PB, Bondly C, Micallef IN. Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jun; 6(6):861-9.
Score: 0.225
-
Assouline SE, Mehta A, Hanel W, Doucet S, Johnston PB, Danilov A, Cooper BW, Chudnovsky A, Ding J, Long T, Stroopinsky D, Berg D, Alinari L. Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Nov; 25(11):788-799.e11.
Score: 0.208
-
Hwang SR, Godby RC, Negaard BJ, Mwangi R, Nedved AN, Barreto JN, Micallef IN, Ansell SM, Porrata L, Durani U, Thanarajasingam G, Habermann TM, Maurer MJ, Johnston PB, Khurana A. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience. Blood Adv. 2025 Feb 25; 9(4):924-932.
Score: 0.206
-
Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Peterson JL, Hoppe BS. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma. Haematologica. 2023 11 01; 108(11):2982-2992.
Score: 0.188
-
Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, Khurana A, Bennani NN, Paludo J, Bisneto JV, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023 08 18; 13(1):127.
Score: 0.185
-
Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy. Blood Adv. 2023 04 25; 7(8):1572-1576.
Score: 0.181
-
Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 06; 23(6):456-462.
Score: 0.179
-
Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Khurana A, Villasboas JC, Johnston PB, Ansell SM, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2023 Aug 01; 116(5):999-1007.
Score: 0.177
-
McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, Bennani N, Thanarajasingam G, Nowakowski G, Porrata L, Thompson C, Micallef I, Johnston P, Ansell S, Paludo J. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023 02; 64(2):371-377.
Score: 0.176
-
Seegobin K, Li Z, Alhaj Moustafa M, Majeed U, Wang J, Jiang L, Kuhlman J, Menke D, Li K, Kharfan-Dabaja MA, Ayala E, Iqbal M, Nowakowski GS, Habermann TM, Witzig TE, Johnston P, Thompson C, Ansell S, Tun HW. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018). Am J Hematol. 2022 09; 97(9):1150-1158.
Score: 0.171
-
Farooqui N, Sy-Go JPT, Miao J, Mehta R, Vaughan LE, Bennani NN, Wang Y, Bansal R, Hathcock MA, Hayman SR, Johnston PB, Villasboas JC, Paludo J, Ansell SM, Leung N, Lin Y, Herrmann SM. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy. Mayo Clin Proc. 2022 07; 97(7):1294-1304.
Score: 0.171
-
Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z, Babadi E, Martinez KE, McCoy GA, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas JC, Lin Y. Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. Am J Hematol. 2022 07; 97(7):E241-E244.
Score: 0.169
-
Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas Bisneto JC, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. J Hematol Oncol. 2022 03 26; 15(1):36.
Score: 0.168
-
Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol. 2022 01; 166:171-179.
Score: 0.165
-
Khurana A, Hathcock M, Habermann TM, Al Saleh AS, Gandhi S, Truong T, Bennani NN, Paludo J, Villasboas JC, Ansell SM, Inwards DJ, Porrata LF, Johnston PB, Micallef I, Lin Y. Lines of therapy before autologous stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin's lymphoma. Am J Hematol. 2021 10 01; 96(10):E386-E389.
Score: 0.161
-
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Markovic SN. Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. Leuk Res. 2019 06; 81:1-9.
Score: 0.137
-
Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92(5):448-453.
Score: 0.118
-
Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nevala W, Markovic SN. Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016 06; 22(6):1017-1023.
Score: 0.110
-
Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013 Jul; 88(7):589-93.
Score: 0.091
-
Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7.
Score: 0.077
-
Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, Dingli D, Dispenzieri A, Gertz M, Greiner C, Hayman S, Inwards D, Johnston P, Lacy M, Litzow M, Porrata L, Winters JL, Kumar S. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant. 2011 Jul; 46(7):943-9.
Score: 0.076
-
Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL, Macon WR, Nowakowski GS, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol. 2010 Sep 20; 28(27):4191-8.
Score: 0.075
-
Porrata LF, Inwards DJ, Micallef IN, Johnston PB, Ansell SM, Hogan WJ, Markovic SN. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin Dev Immunol. 2010; 2010:914945.
Score: 0.073
-
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 01; 115(13):2578-85.
Score: 0.071
-
Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008 Oct 10; 26(29):4814-9.
Score: 0.065
-
Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008 Jul; 14(7):807-16.
Score: 0.065
-
Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008 Feb 01; 111(3):1085-93.
Score: 0.062
-
Kitzmann AS, Pulido JS, Mohney BG, Baratz KH, Grube T, Marler RJ, Donaldson MJ, O'Neill BP, Johnston PB, Johnson KM, Dixon LE, Salomao DR, Cameron JD. Intraocular use of rituximab. Eye (Lond). 2007 Dec; 21(12):1524-7.
Score: 0.060
-
Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Jan; 7(4):315-8.
Score: 0.058
-
Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, Lewis JT, Markovic SN, Porrata LF, White WL, Witzig TE, Ristow K, Habermann TM. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1794-9.
Score: 0.057
-
Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Litzow MR, Gastineau DA, Markovic SN. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol. 2006 Jun; 133(6):628-33.
Score: 0.056
-
Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013 Jan; 19(1):87-93.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|